Tirzepatide
Metabolic & Weight LossFDA ApprovedAlso known as: GLP-2T, GIP/GLP-1, ION-2T, GLP-2, Tirzepatide, PEP-2T, RC-2T, Dual Agonist, Ion Peptide Tirzepatide, Tirz, GIP/GLP
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid synthetic peptide based on the native GIP sequence with modifications that confer activity at both GIP and GLP-1 receptors.
Reconstitution Calculator for Tirzepatide
Pre-filled · 10mg vial · 2500mcg dose
Overview
At A Glance
Dual GLP-1 and GIP Receptor Agonism…
Overview
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid synthetic peptide based on the native GIP sequence with modifications that confer activity at both GIP and GLP-1 receptors. Tirzepatide features a C20 fatty diacid moiety attached via a linker to facilitate albumin binding, resulting in a plasma half-life of approximately 5 days that supports once-weekly subcutaneous dosing. Tirzepatide is FDA-approved under two brand names: Mounjaro (for type 2 diabetes mellitus, approved May 2022) and Zepbound (for chronic weight management, approved November 2023). It is manufactured by Eli Lilly and Company and represents the first-in-class dual GIP/GLP-1 receptor agonist to reach the market. The SURMOUNT clinical trial program established tirzepatide as the most effective pharmacological weight loss agent to date. In the SURMOUNT-1 trial, participants with obesity or overweight (without diabetes) receiving tirzepatide 15 mg weekly achieved a mean body weight reduction of 22.5% from baseline at 72 weeks, compared to 2.4% with placebo — a treatment difference of 20.1 percentage points. Notably, 36.2% of participants in the 15 mg group achieved 25% or greater total body weight loss, approaching the magnitude historically seen only with bariatric surgery (PMID: 35658024). The SURMOUNT-2 trial evaluated tirzepatide in adults with type 2 diabetes and obesity, demonstrating mean weight loss of 14.7% with tirzepatide 15 mg versus 3.2% with placebo at 72 weeks, along with significant HbA1c improvement (PMID: 36519860). The SURMOUNT-3 trial studied tirzepatide following an intensive 12-week lifestyle intervention, showing that tirzepatide maintained and extended initial weight loss while placebo recipients regained weight (PMID: 37840095). A key differentiating feature of tirzepatide compared to pure GLP-1 receptor agonists such as semaglutide is the GIP receptor agonist component. GIP signaling in adipose tissue is proposed to improve lipid metabolism and may protect against the loss of lean body mass that accompanies caloric restriction and weight loss. Preclinical and early clinical data suggest that tirzepatide-treated patients lose a greater proportion of fat mass relative to lean mass compared to GLP-1-only agents, though this finding requires further validation in dedicated body composition studies. Tirzepatide achieved the highest absolute weight loss of any anti-obesity medication in clinical trials. At the 15 mg dose, mean absolute weight loss was approximately 24 kg (52 lbs) at 72 weeks in SURMOUNT-1. The gastrointestinal side effect profile is similar to GLP-1 receptor agonists, with nausea being the most common adverse event, generally mild to moderate and diminishing over time with dose titration.
Potential Research Fields
Chemical Information
IUPAC Name
Not fully specified (proprietary sequence)
CAS Number
2023788-19-2
Molecular Formula
C225H348N48O68
Molecular Mass
4813.49 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction Matrix
Contraindications
Personal or family history of MTC. MEN 2 syndrome. History of pancreatitis. Severe GI disease. Pregnancy or breastfeeding.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$49.00
up to $349.99
$1.9900
6
18
vial
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
RC-2T 60mg | vial | 60mg vial● In Stock | $299.99BEST | $5.000 | ||
 |
Pep-2T 10mg (Tirzepatide) | vial | 1 vial● In Stock | $94.99 | $9.499 | ||
|
|
Pep-2T 60mg (Tirzepatide) | vial | 1 vial● In Stock | $299.99 | $5.000 | ||
 |
Tirzepatide (ION-2T) 10mg | vial | 1 vial● In Stock | $49.00 | $4.900 | — | |
|
|
Tirzepatide (ION-2T) 20mg | vial | 1 vial● Out of Stock | $85.00 | $4.250 | — | Sign in for stock alert |
|
|
Tirzepatide (ION-2T) 30mg | vial | 1 vial● Out of Stock | $108.50 | $3.617 | — | Sign in for stock alert |
|
|
Tirzepatide (ION-2T) 40mg | vial | 1 vial● In Stock | $129.00 | $3.225 | — | |
|
|
Tirzepatide (ION-2T) 60mg | vial | 1 vial● In Stock | $149.00 | $2.483 | — | |
|
|
Tirzepatide (ION-2T) 100mg | vial | 1 vial● Out of Stock | $199.00 | $1.990 | — | Sign in for stock alert |
 |
Tirzepatide 10mg | vial | 1 vial● In Stock | $79.99 | $7.999 | — | |
|
|
Tirzepatide 10mg | vial | 1 vial● In Stock | $89.99 | $8.999 | — | |
 |
Tirzepatide (GLP-2 TZ) 10mg Vial | vial | 1 vial● In Stock | $100.00 | $10.000 | ||
|
|
Tirzepatide (GLP-2 TZ) 20mg Vial | vial | 1 vial● In Stock | $184.00 | $9.200 | ||
 |
GLP-Tirz (Tirzepatide) 5mg | vial | 5mg vial● In Stock | $59.99 | $11.998 | ||
|
|
GLP-Tirz (Tirzepatide) 10mg | vial | 10mg vial● In Stock | $89.99 | $8.999 | ||
|
|
GLP-Tirz (Tirzepatide) 15mg | vial | 15mg vial● In Stock | $109.99 | $7.333 | ||
|
|
GLP-Tirz (Tirzepatide) 30mg | vial | 30mg vial● In Stock | $189.99 | $6.333 | ||
|
|
GLP-Tirz (Tirzepatide) 60mg | vial | 60mg vial● In Stock | $349.99 | $5.833 |
Tracking since Mar 13, 2026 · 16 data points
Price History
4 data pointsVendors Selling Tirzepatide
Ion Peptide
VANDL Labs
BioMyst Labs
Optimum Formula
Nova Peptides
ResearchChemHQ
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View AllAOD-9604
Metabolic & Weight LossPhase 3AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide fragment of human growth hormone (hGH) corresponding to residues 177-191 of the hGH molecule plus a tyrosine addition at the N-terminus (sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe).
Cagrilintide
Metabolic & Weight LossPhase 3Cagrilintide (also known as AM833, development code NN9838) is a long-acting amylin analog developed by Novo Nordisk as a next-generation weight-management therapy, designed to be co-administered with the GLP-1 receptor agonist semaglutide in a fixed-ratio combination known as CagriSema.
HGH Fragment 176-191
Metabolic & Weight LossPhase 2HGH Fragment 176-191 (also written HGH Frag 176-191, hGH Fragment 176-191, and frequently appearing in clinical literature as AOD-9604 — "Anti-Obesity Drug 9604") is a synthetic peptide corresponding to the C-terminal 15-amino-acid region of the 191-amino-acid human growth hormone (hGH) molecule, with an additional N-terminal tyrosine residue added for stability and biological activity.
Retatrutide
Metabolic & Weight LossPhase 3Retatrutide (also coded LY3437943) is an investigational once-weekly triple-agonist at the GLP-1, GIP, and glucagon receptors — the third-generation incretin-based therapy developed by Eli Lilly.
Semaglutide
Metabolic & Weight LossFDA ApprovedSemaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a molecular weight of 4113.58 Da and CAS number 910463-68-2.
Side-by-Side Comparisons
All ComparisonsView Full Dosage Guide →
Protocols, calculator & safety for Tirzepatide
Related Articles
All PostsAquasome Nanotechnology and Oral Peptides: The Mechanism, the Research, and the 10 Compounds It Actually Works For
how aquasome 3-layer nano-encapsulation lets peptides like retatrutide, bpc-157, and tb-500 survive the gut. pubmed-backed deep dive on the 10 compounds it works for.
5/20/2026Retatrutide Protocol Guide 2026: Dosing, Titration, Side Effects, Week-by-Week
A standalone beginner protocol for retatrutide — Eli Lilly's triple GLP-1/GIP/glucagon agonist. Dose math, week-by-week titration, side-effect management, realistic expectations, and where to source research-grade material.
5/19/2026Semaglutide to Tirzepatide Switch Protocol: Dose Conversion + Week-by-Week Plan
Switching from Wegovy/Ozempic to Mounjaro/Zepbound is the most-asked transition in the GLP-1 community. Here is the dose-conversion math, the week-by-week protocol, and the side-effect pitfalls to plan for.
5/19/2026Research Score
626 PubMed studies
Quality Indicators
Data Completeness
100%COA Verification
10
Verified COAs
2
Vendors w/ COA
High verification rate (83%)
Latest test: 3/1/2026
Research Credibility
Well-researched compound
Quick Facts
Half-Life
~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification
Molecular Weight
4813.49 g/mol
Administration
Subcutaneous (weekly)
CAS Number
2023788-19-2
Trial Phase
FDA Approved
Safety Profile
Common Side Effects
- • Nausea (most common, 24-33% depending on dose, typically transient)
- • Diarrhea (17-23%)
- • Vomiting (6-13%, more common during titration)
- • Decreased appetite (considered both effect and side effect)
- • Constipation (6-11%)
- • Injection site reactions (3-7%)
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is Tirzepatide used for in research?
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid synthetic peptide based on the native GIP sequence with modifications that confer activity at both GIP and GLP-1 receptors. Tirzepatide features a C20 fatty diacid moiety attached via a linker to facilitate albumin binding, resulting in a plasma half-life of approximately 5 days that supports once-weekly subcutaneous dosing.
Tirzepatide is FDA-approved under two brand names: Mounjaro (for type 2 diabetes mellitus, approved May 2022) and Zepbound (for chronic weight management, approved November 2023). It is manufactured by Eli Lilly and Company and represents the first-in-class dual GIP/GLP-1 receptor agonist to reach the market.
The SURMOUNT clinical trial program established tirzepatide as the most effective pharmacological weight loss agent to date. In the SURMOUNT-1 trial, participants with obesity or overweight (without diabetes) receiving tirzepatide 15 mg weekly achieved a mean body weight reduction of 22.5% from baseline at 72 weeks, compared to 2.4% with placebo — a treatment difference of 20.1 percentage points. Notably, 36.2% of participants in the 15 mg group achieved 25% or greater total body weight loss, approaching the magnitude historically seen only with bariatric surgery (PMID: 35658024).
The SURMOUNT-2 trial evaluated tirzepatide in adults with type 2 diabetes and obesity, demonstrating mean weight loss of 14.7% with tirzepatide 15 mg versus 3.2% with placebo at 72 weeks, along with significant HbA1c improvement (PMID: 36519860). The SURMOUNT-3 trial studied tirzepatide following an intensive 12-week lifestyle intervention, showing that tirzepatide maintained and extended initial weight loss while placebo recipients regained weight (PMID: 37840095).
A key differentiating feature of tirzepatide compared to pure GLP-1 receptor agonists such as semaglutide is the GIP receptor agonist component. GIP signaling in adipose tissue is proposed to improve lipid metabolism and may protect against the loss of lean body mass that accompanies caloric restriction and weight loss. Preclinical and early clinical data suggest that tirzepatide-treated patients lose a greater proportion of fat mass relative to lean mass compared to GLP-1-only agents, though this finding requires further validation in dedicated body composition studies.
Tirzepatide achieved the highest absolute weight loss of any anti-obesity medication in clinical trials. At the 15 mg dose, mean absolute weight loss was approximately 24 kg (52 lbs) at 72 weeks in SURMOUNT-1. The gastrointestinal side effect profile is similar to GLP-1 receptor agonists, with nausea being the most common adverse event, generally mild to moderate and diminishing over time with dose titration.
What forms does Tirzepatide come in?
Tirzepatide is available in vial form.
How much does Tirzepatide cost?
Prices start at $49.00 across 6 verified vendors.
How do I compare Tirzepatide vendors?
Compare prices, payment methods, shipping, and COA scores across 6 vendors.
Research Tools
Related Compounds
View AllAOD-9604
Metabolic & Weight LossPhase 3AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide fragment of human growth hormone (hGH) corresponding to residues 177-191 of the hGH molecule plus a tyrosine addition at the N-terminus (sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe).
Cagrilintide
Metabolic & Weight LossPhase 3Cagrilintide (also known as AM833, development code NN9838) is a long-acting amylin analog developed by Novo Nordisk as a next-generation weight-management therapy, designed to be co-administered with the GLP-1 receptor agonist semaglutide in a fixed-ratio combination known as CagriSema.
HGH Fragment 176-191
Metabolic & Weight LossPhase 2HGH Fragment 176-191 (also written HGH Frag 176-191, hGH Fragment 176-191, and frequently appearing in clinical literature as AOD-9604 — "Anti-Obesity Drug 9604") is a synthetic peptide corresponding to the C-terminal 15-amino-acid region of the 191-amino-acid human growth hormone (hGH) molecule, with an additional N-terminal tyrosine residue added for stability and biological activity.
Retatrutide
Metabolic & Weight LossPhase 3Retatrutide (also coded LY3437943) is an investigational once-weekly triple-agonist at the GLP-1, GIP, and glucagon receptors — the third-generation incretin-based therapy developed by Eli Lilly.
Semaglutide
Metabolic & Weight LossFDA ApprovedSemaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a molecular weight of 4113.58 Da and CAS number 910463-68-2.
Side-by-Side Comparisons
All ComparisonsCompare Tirzepatide head-to-head: mechanism, half-life, dosing, safety, and live pricing.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.